Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
As their use grows, so do questions about GLP-1 and eating disorders, particularly how appetite-suppressing drugs might interact with conditions that involve disrupted hunger cues, restrictive behaviors, or cycles of bingeing and compensatory actions
10.3390/toxins13090667 60
Srinivasan is a bioengineer who led the VIBES study while working at MIT
In this episode, TRC Healthcare Associate Editor and Clinical Pharmacist Vickie Danaher, PharmD, discusses how orforglipron, the second oral GLP-1 agonist for weight loss, stacks up against oral semaglutide in terms of dosing, efficacy, safety, and more
Over time, this contributes to weight gain, insulin resistance, and metabolic dysfunction
Nat Aging 1(12):11621174 Shri SR et al (2023) Role of GSK-3 inhibitors: new promises and opportunities for Alzheimers disease
